Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. (Q38087392)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

title

Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Hyo Sup Shim

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

Byoung Chul Cho

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1

Sun Min Lim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

4

Ross A Soo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

English

0 references

publication date

1 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

377-386

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Lung cancer in never smokers: change of a mindset in the molecular era.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Genetic changes in squamous cell lung cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

FGFR1 expression and gene copy numbers in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Expression of the FGFR1 gene in human breast-carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

Functional FGFR4 Gly388Arg Polymorphism Predicts Prognosis in Lung Adenocarcinoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.12.190

21 January 2018

Identifiers

DOI

10.2217/FON.12.190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23469973%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference